Gilead and Galapagos shares hit as filgotinib disappoints

Gilead and Galapagos' late-stage trial of their ulcerative colitis drug filgotinib has hit its target – but shares in both companies were down after data suggested the drug may struggle for

Lilly, Galapagos suspend trials as COVID-19 hits health syst...

Novartis’ $100m bet on eczema drug fails as MOR106 developme...

Galapagos and MorphoSys have announced that they are ending the clinical development programme for their drug MOR106 in atopic dermatitis (also known as eczema).

Gilead says arthritis drug filgotinib fails in follow-up use...

Gilead invests $5.1bn in Belgian biotech Galapagos

Belgian biotech Galapagos has signed a shiny new deal with Gilead to develop inflammatory disease and rheumatoid arthritis drugs, where the big US pharma will pay $3.95 billion up front and

Galapagos shares surge on RA drug trial results

Shares in the Belgian biotech Galapagos have surged after a late stage trial of filgotinib, a rheumatoid arthritis drug it is developing with Gilead, met all its endpoints.